Asia Pacific Bio-Intelligence and Payer+Provider form Partnership

PHILADELPHIA – April 16, 2012: Asia Pacific Bio-Intelligence LLC and Payer+Provider Syndicate have formed a bilateral strategic partnership. Seth J. Goldenberg, Ph.D., President of Asia Pacific Bio-Intelligence (APBI), announced, “The partnership between Payer+Provider and APBI will extend the services both firms can offer to clients operating in China’s healthcare space. Combining regulatory strategies for market entry with cutting-edge health service research will create a unique and powerful offering.” Adam C. Powell, Ph.D., President of Payer+Provider, declared, “Our partnership with APBI is a demonstration of our commitment to the Chinese market. Working with APBI will enhance our ability to serve clients tackling problems related to medical devices and pharmaceuticals, and will provide us greater presence within China.” APBI maintains offices in Shanghai, China and Philadelphia, Pennsylvania.

Asia Pacific Bio Intelligence, LLC (APBI), a privately held consulting and project management company, was established in 2011 to help bridge U.S. and Chinese Healthcare, Pharmaceutical, Medical Device, Regulatory, Medical Communications, and Education Organizations. APBI is a complete solutions provider for healthcare, pharmaceutical, and medical device industries within the U.S. and China, providing services for: market analysis, distributor identification, partner identification, regulatory strategy and approval, healthcare provider training, hiring of key staff and office setup, and many other services to help you grow your business in China or the U.S. APBI is committed to helping companies overcome the bureaucratic, linguistic, and cultural differences that typically impede entering a foreign market in a timely and cost effective manner. With former U.S. FDA and SFDA members on staff APBI is uniquely poised to help with the changes. For more details please email info@ap-bi.com or visit www.ap-bi.com.

Contact Payer+Provider for further details.

Comments are closed.